iRhythm Technologies, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRTC research report →
Range $160 – $206
Price Chart
About the company
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system.
- CEO
- Quentin S. Blackford
- IPO
- 2016
- Employees
- 2,400
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on IRTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.18B
- P/E
- -76.64
- Fwd P/E
- 74.24
- PEG
- 0.28
- P/S
- 3.48
- P/B
- 16.76
- EV/EBITDA
- 3621.63
- Div Yield
- 0.00%
- Gross Margin
- 72.26%
- Op Margin
- -4.47%
- Net Margin
- -4.52%
- ROE
- -22.80%
- ROIC
- -4.23%
Latest fiscal year · YoY change
- Revenue
- $747.14M+26.2%
- Gross Profit
- $527.25M+29.4%
- Op Income
- $-36,810,000
- Net Income
- $-44,551,000+60.7%
- EPS
- $-1.39+61.7%
- OCF Growth
- +2285.3%
- FCF Growth
- +175.8%
- 52W High
- $192.47
- 52W Low
- $82.85
- 50D MA
- $109.60
- 200D MA
- $118.32
- Beta
- 1.40
- RSI (14)
- 40
- Avg Volume
- 676.06K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
iRhythm posted double-digit revenue growth and record adjusted profitability in Q3, but management pulled back the timing of its next-generation MCT filing and said VitalConnect integration will temporarily complicate AT growth.· November 5, 2026
- Q3 revenue rose 14.9% year over year to $221.6 million, driven by Zio Monitor strength and broad-based demand.
- Gross margin hit 74.2% and adjusted EBITDA margin reached 23.1%, both reflecting strong operating leverage.
- VitalConnect closed on October 5 and immediately expanded iRhythm’s MCT portfolio, but the company no longer plans to file Zio MCT later this year.
- Zio AT revenue was roughly flat year over year, and management said some customers delayed onboarding while they waited to see the combined VitalConnect/iRhythm offering.
- Full-year 2026 revenue guidance was raised to $890 million to $895 million; adjusted EBITDA margin guidance was raised to 15.5% to 16%.
Third-quarter 2026 revenue was $221.6 million, up 14.9% year over year. Gross margin was 74.2%, up 310 basis points year over year, and adjusted EBITDA was $51.2 million, or 23.1% of revenue, up more than 1,100 basis points year over year. GAAP net loss was $29.9 million, or $0.90 per diluted share, versus a GAAP net loss of $5.2 million, or $0.16 per diluted share, in Q3 2025; adjusted net income was $27.8 million, or $0.82 per diluted share, versus adjusted net loss of $2.0 million, or $0.06 per diluted share, a year ago. Free cash flow was negative $11.5 million, but would have been positive $38.5 million excluding a one-time $50 million IP litigation settlement payment. The company ended the quarter with $560.7 million in unrestricted cash, cash equivalents, and marketable securities, and it also added a new $300 million revolving credit facility on November 3. For Q4 and full-year 2026, management raised revenue guidance to $890 million to $895 million, expects total company gross margin above 70% in Q4, raised adjusted EBITDA margin guidance to 15.5% to 16%, and said free cash flow should be positive in Q4 and higher year over year for 2026 excluding one-time litigation and transaction items. Management expects Q4 Zio Monitor growth in the mid-teens, about $16 million of VitalConnect revenue, and Zio AT sequentially flat to Q3 on volumes but down about 10% in dollars because of a prior-year benefit that will not repeat.
Quentin Blackford said the quarter showed iRhythm’s core business is still growing well and generating strong operating leverage, while the VitalConnect acquisition meaningfully broadens the company’s MCT opportunity. His tone was candid about execution gaps: he said the company has “not delivered” on Zio MCT timing as hoped and acknowledged the delay has frustrated investors. At the same time, he emphasized that iRhythm now has an immediate MCT platform, broader market reach, and a clearer near-term plan to integrate VitalConnect and expand into adjacent monitoring opportunities.
Dan Wilson emphasized strong top-line performance, record profitability, and disciplined expense management. He cited 74.2% gross margin, 23.1% adjusted EBITDA margin, $51.2 million of adjusted EBITDA, and $560.7 million of unrestricted cash and marketable securities, noting that free cash flow would have been positive $38.5 million excluding the $50 million litigation settlement. He also highlighted the new $300 million revolving credit facility and said 2027 priorities are to sustain gross margin above 70%, keep adjusted EBITDA margin at least 15%, and invest behind growth rather than prioritize near-term cost synergies in VitalConnect.
Analysts focused heavily on why Zio AT slowed, whether customers were delaying decisions because of VitalConnect, and how long the disruption might last. Management said the slowdown was mostly in new account onboarding, not existing accounts, because customers do not want to integrate twice before the platforms are combined. They also said the combined platform should begin becoming available in mid-1Q 2027, that Zio AT is likely to remain pressured for a quarter or two, and that Zio MCT filing is now expected in 2027 rather than later this year. Several analysts also pressed on the 2027 revenue math and whether VitalConnect could offset AT weakness; management replied that the organic business is still targeted to reach approximately $1 billion next year, with Zio Monitor growing in the mid-teens, Zio AT flat, and VitalConnect growing slightly above the organic company rate.
The bull case from this call is that iRhythm’s core Zio Monitor business is still expanding at a mid-teens rate, with new accounts contributing about 51% of year-over-year volume growth and international, primary care, and innovative channels all still gaining traction. VitalConnect gives the company an immediately broader MCT portfolio and could help capture a market segment management estimates is about 25% of the MCT market that needs capabilities like live look-in and 30-day monitoring. Management also pointed to strong clinical evidence, improving cash generation, and long-term leverage from its AI algorithm and operating scale.
The main risk is execution: management admitted Zio MCT timelines have slipped multiple times, and it now will not be filed later this year, with submission pushed to 2027. Zio AT is already softening as customers wait for the combined platform, and management expects that pressure to persist in the near term and possibly for a quarter or two after integration. There is also uncertainty around how quickly VitalConnect can be integrated, scaled nationally, and translated into stronger revenue without disrupting the core business.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.2%
- Shares Outstanding
- 33.19M
- Float Shares
- 30.94M
of shares held by institutions
320 13F filers
Buy/sell ratio 0.45. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IRTC, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Richard BlumenthalSenate · CT | Sell | Aug 14, 25 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 14, 25 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 14, 25 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 14, 25 | Filing → |
| Richard BlumenthalSenate · CT | Sell | Aug 14, 25 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 3.31M | ▲ 70.42K |
| Blackrock, Inc. | 3.01M | ▲ 21.05K |
| Artisan Partners Limited Partnership | 2.20M | ▲ 535.56K |
| Rtw Investments, LP | 2.18M | ▲ 514.13K |
| Vanguard Portfolio Management LLC | 1.98M | ▲ 67.23K |
| Vanguard Capital Management LLC | 1.47M | ▲ 1.83K |
| Millennium Management LLC | 1.41M | ▼ 201.56K |
| Bnp Paribas Asset Management Holding S.A. | 1.12M | ▲ 250.69K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 944.52K | ▼ 102.94K |
| Eventide Asset Management, LLC | 909.19K | ▲ 28.85K |
| State Street Corp | 863.69K | ▲ 7.17K |
| Geode Capital Management, LLC | 860.51K | ▼ 21.39K |
Held by 370 ETFs
Biggest fund positions in IRTC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | TALWALKAR ABHIJIT Y | buy | 7,900 |
| Sep 2, 26 | Wilson Daniel G. | sell | 773 |
| Aug 7, 26 | Blackford Quentin S. | other | 48,534 |
| Aug 10, 26 | Blackford Quentin S. | sell | 26,859 |
| Aug 7, 26 | Murphy Patrick Michael | other | 13,589 |
| Aug 10, 26 | Murphy Patrick Michael | sell | 7,093 |
| Aug 7, 26 | Patterson Chad | other | 13,589 |
| Aug 10, 26 | Patterson Chad | sell | 7,093 |
| Aug 7, 26 | Shrishrimal Sumi | other | 9,706 |
| Aug 10, 26 | Shrishrimal Sumi | sell | 5,372 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IRTC coverage
Recent articles, reports, and earnings notes.
No research on IRTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRTC report →IRHYTHM HOLDINGS, INC. IRTC INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 30.7% Share Drop
feeds.newsfilecorp.com · Nov 19
iRhythm Announces $100 Million Accelerated Share Repurchase Agreement
globenewswire.com · Nov 17
IRHYTHM HOLDINGS, INC. INVESTIGATION: IRTC Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
businesswire.com · Nov 13
30,163 iRhythm Technologies $IRTC Shares Sold by Allspring Global Investments Holdings LLC
defenseworld.net · Nov 13
iRhythm Announces Approval of $200 Million Share Repurchase Program
globenewswire.com · Nov 11
IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)
prnewswire.com · Nov 6
iRhythm Holdings to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 6
What iRhythm Technologies (IRTC) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.